Prescription medication · SGLT2 Inhibitor
empagliflozin
Also sold as Jardiance.
Data updated 2026-05-15
- 61,560
- FDA reportsOften reported
- 10
- InteractionsSeveral interactions
- $19.55
- Brand price (NADAC)
What the data shows
empagliflozin (Jardiance) is a prescription SGLT2 Inhibitor, more reported than most tracked drugs (61,560 FDA reports), with 10 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$19.55/unit
Generic Available
No
BOEHRINGER INGELHEIM
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Information not available.
Common side effects
Urinary tract infection, Yeast infection (in women), Diarrhea
Key warnings
No specific warnings noted. Always follow your prescriber's instructions.
Side Effects (from patient reports)
Based on 61,560 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for empagliflozin, by number of reports
- Diabetic Ketoacidosis
Diabetic Ketoacidosis
3,773 reports
- Nausea
Nausea
3,212 reports
- Blood Glucose Increased
Blood Glucose Increased
3,043 reports
- Diarrhoea
Diarrhoea
2,806 reports
- Weight Decreased
Weight Decreased
2,749 reports
- Fatigue
Fatigue
2,590 reports
- Dizziness
Dizziness
2,417 reports
- Vomiting
Vomiting
2,399 reports
- Dyspnoea
Dyspnoea
2,076 reports
- Fungal Infection
Fungal Infection
2,057 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for empagliflozin each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where empagliflozin sits
empagliflozin has more FDA adverse-event reports than 77% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is empagliflozin; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 61,560 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
61,560
Reports Mentioning Death
3,028
4.9% of reports — not proof of cause
Hospitalization Reports
20,281
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | DIABETIC KETOACIDOSIS | 3,773 |
| 2 | NAUSEA | 3,212 |
| 3 | BLOOD GLUCOSE INCREASED | 3,043 |
| 4 | DIARRHOEA | 2,806 |
| 5 | WEIGHT DECREASED | 2,749 |
| 6 | FATIGUE | 2,590 |
| 7 | DIZZINESS | 2,417 |
| 9 | VOMITING | 2,399 |
| 11 | DYSPNOEA | 2,076 |
| 12 | FUNGAL INFECTION | 2,057 |
| 13 | EUGLYCAEMIC DIABETIC KETOACIDOSIS | 1,935 |
| 14 | URINARY TRACT INFECTION | 1,814 |
| 15 | HEADACHE | 1,680 |
| 16 | ACUTE KIDNEY INJURY | 1,599 |
| 17 | ASTHENIA | 1,483 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Known Drug Interactions
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] . Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. ( 7 ) Drugs that...
Mechanism: Using these medicines together can increase the risk of a dangerous buildup of lactic acid in the blood. This risk is higher when other factors, such as alcohol, change how the body handles metformin.
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Mechanism: Dolutegravir blocks the kidneys from removing metformin from the body. This can cause metformin levels to rise, which increases the risk of a serious condition called lactic acidosis.
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Mechanism: Ranolazine interferes with how the kidneys clear metformin from your system. This can lead to higher levels of metformin in your blood and a higher risk of a dangerous acid buildup.
7 DRUG INTERACTIONS See Table 4 for clinically relevant interactions with SYNJARDY or SYNJARDY XR. Table 4 Clinically Relevant Interactions with SYNJARDY or SYNJARDY XR Carbonic Anhydrase Inhibitors Clinical Impact Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with SYNJARDY or SYNJARDY XR may increase the risk of lactic acidosis.
Mechanism: Taking certain medications like topiramate along with your diabetes medicine can lower your blood's ability to balance acid. This increases the risk of a serious condition called lactic acidosis.
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Mechanism: Cimetidine stops the kidneys from getting rid of metformin as quickly as they should. This can cause metformin to build up in your blood and increase the risk of a serious acid problem.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What are the common side effects of empagliflozin?
Does empagliflozin interact with other medications?
What drug class is empagliflozin?
Related Medications in SGLT2 Inhibitor
Other drugs grouped near empagliflozin - same-class peers and common alternatives.
acarbose
Precose
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.
Compare with empagliflozin →
alogliptin
Nesina
Compare with empagliflozin →
bromocriptine
Cycloset
Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.
Compare with empagliflozin →
canagliflozin
Invokana
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Compare with empagliflozin →
colesevelam
Welchol
Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.
Compare with empagliflozin →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for empagliflozin: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 61,560.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 4.92%.
- secukinumab Δ 0.01 pts · 157,236 reports · IL-17A Inhibitor (Biologic) 4.93%death share
- capsaicin Δ 0.07 pts · 3,030 reports · Topical Analgesic 4.85%death share
- montelukast Δ 0.10 pts · 78,359 reports · Leukotriene Receptor Antagonist 4.82%death share
- felbamate Δ 0.10 pts · 1,714 reports · Anticonvulsant 5.02%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on empagliflozin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for empagliflozin
The FDA label for empagliflozin (sold under brand names such as Jardiance) classifies it as a prescription-only medication in the SGLT2 Inhibitor class. Regulatory labeling describes its approved uses and the patient populations studied in pre-market trials. Official labeling lists 10 commonly reported side effects, including Urinary tract infection, Yeast infection (in women), Diarrhea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 61,560 voluntary reports. The database also lists 10 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: January 30, 2026
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages